Published online before print July 7, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article |
Pulmonary and Critical Care Medicine Division, Department of Internal Medicine, Ann Arbor Veterans Affairs Medical Center and University of Michigan Medical Center, Ann Arbor
@ To whom correspondence should be addressed. E-mail: mgyetko{at}umich.edu.
Leukocytes express both urokinase-type plasminogen activator (uPA) and the urokinase receptor (uPAR, CD87). We have shown that neutrophil recruitment to the lung during P. aeruginosa pneumonia is impaired in uPAR-deficient (uPAR-/-) mice but is normal in uPA-/- mice. However, both uPA-/- mice and uPAR-/- mice have impaired lung clearance of P. aeruginosa compared with wild-type (WT) mice. To determine the role of uPA and uPAR in antibacterial host defense, we compared neutrophil bacterial-phagocytosis, respiratory burst, and degranulation among uPA-/-, uPAR-/-, and WT mice. Neutrophil phagocytosis was significantly diminished comparing uPA-/- and uPAR-/- mice with WT mice at all time points. The generation of superoxide by both uPA-/- and uPAR-/- neutrophils was about half of that seen in WT neutrophils. Degranulation of azurophilic granules was significantly diminished in uPA-/- neutrophils compared with either uPAR-/- or WT neutrophils. By contrast, agonist-stimulated release of specific granules was not diminished in either uPA-/- or uPAR-/- mice compared with WT. We conclude that the uPA/uPAR system modulates several of the crucial steps in neutrophil activation that result in bacterial killing and effective innate host defense.
Key Words: cellular activation • phagocytosis • inflammation • transgenic/knockout
This article has been cited by other articles:
 |
|
 |
|
  W. J. Wiersinga, L. M. Kager, J. W. R. Hovius, G. J. W. van der Windt, A. F. de Vos, J. C. M. Meijers, J. J. Roelofs, A. Dondorp, M. Levi, N. P. Day, et al. Urokinase Receptor Is Necessary for Bacterial Defense against Pneumonia-Derived Septic Melioidosis by Facilitating Phagocytosis J. Immunol., March 15, 2010; 184(6): 3079 - 3086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. T. H. Roelofs, K. M. A. Rouschop, G. J. D. Teske, G. T. M. Wagenaar, N. Claessen, J. J. Weening, T. van der Poll, and S. Florquin Endogenous tissue-type plasminogen activator is protective during ascending urinary tract infection Nephrol. Dial. Transplant., March 1, 2009; 24(3): 801 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-L. Tang, A. Vararattanavech, and S.-M. Tan Urokinase-type Plasminogen Activator Receptor Induces Conformational Changes in the Integrin {alpha}M{beta}2 Headpiece and Reorientation of Its Transmembrane Domains J. Biol. Chem., September 12, 2008; 283(37): 25392 - 25403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yende, D. C. Angus, J. Ding, A. B. Newman, J. A. Kellum, R. Li, R. E. Ferrell, J. Zmuda, S. B. Kritchevsky, T. B. Harris, et al. 4G/5G Plasminogen Activator Inhibitor-1 Polymorphisms and Haplotypes Are Associated with Pneumonia Am. J. Respir. Crit. Care Med., December 1, 2007; 176(11): 1129 - 1137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Elia, E. Cassol, N. Sidenius, F. Blasi, A. Castagna, G. Poli, and M. Alfano Inhibition of HIV replication by the plasminogen activator is dependent on vitronectin-mediated cell adhesion J. Leukoc. Biol., November 1, 2007; 82(5): 1212 - 1220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Suelves, B. Vidal, A. L. Serrano, M. Tjwa, J. Roma, R. Lopez-Alemany, A. Luttun, M. M. de Lagran, M. A. Diaz, M. Jardi, et al. uPA deficiency exacerbates muscular dystrophy in MDX mice J. Cell Biol., September 7, 2007; 178(6): 1039 - 1051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Leduc, N. Beaufort, S. de Bentzmann, J.-C. Rousselle, A. Namane, M. Chignard, and D. Pidard The Pseudomonas aeruginosa LasB Metalloproteinase Regulates the Human Urokinase-Type Plasminogen Activator Receptor through Domain-Specific Endoproteolysis Infect. Immun., August 1, 2007; 75(8): 3848 - 3858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Madsen, G. M. S. Ferraris, A. Andolfo, O. Cunningham, and N. Sidenius uPAR-induced cell adhesion and migration: vitronectin provides the key J. Cell Biol., June 21, 2007; 177(5): 927 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Fradin, A. L. Mavor, G. Weindl, M. Schaller, K. Hanke, S. H. E. Kaufmann, H. Mollenkopf, and B. Hube The Early Transcriptional Response of Human Granulocytes to Infection with Candida albicans Is Not Essential for Killing but Reflects Cellular Communications Infect. Immun., March 1, 2007; 75(3): 1493 - 1501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Heymans, M. Pauschinger, A. De Palma, A. Kallwellis-Opara, S. Rutschow, M. Swinnen, D. Vanhoutte, F. Gao, R. Torpai, A. H. Baker, et al. Inhibition of Urokinase-Type Plasminogen Activator or Matrix Metalloproteinases Prevents Cardiac Injury and Dysfunction During Viral Myocarditis Circulation, August 8, 2006; 114(6): 565 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yasuda, N. Morokawa, G. W. Wong, A. Rossi, M. S. Madhusudhan, A. Sali, Y. S. Askew, R. Adachi, G. A. Silverman, S. A. Krilis, et al. Urokinase-type plasminogen activator is a preferred substrate of the human epithelium serine protease tryptase {epsilon}/PRSS22 Blood, May 15, 2005; 105(10): 3893 - 3901. [Abstract] [Full Text] [PDF]
|
|
